ClinicalTrials.gg
Not yet recruitingNCT05847582mSTARSUpdated Nov 18, 2026

mHealth-supported Skills Training for Alcohol-Related Suicidality Phase 3

An interventional study of Standard inpatient psychiatric care and Inpatient Skills Training in Alcohol Drinking and Suicide, sponsored by Duke University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Duke University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 18, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Suicide is a high priority public health problem and an increasingly prevalent alcohol-related consequence. One-third of people who die by suicide consume alcohol at hazardous rates in the year preceding death. Most people in an acute suicide crisis who present for treatment are admitted to acute psychiatric hospitalization. Yet, the 30-day period following discharge from hospitalization is by far the riskiest period for another suicide crisis. The specific aim for this project is to evaluate the feasibility and acceptability of an intervention called mHealth-supported Skills Training for Alcohol-Related Suicidality (mSTARS). Thirty-five inpatients with suicidal thoughts or behaviors who misuse alcohol will be randomized to one of three study conditions -- mSTARS, treatment as usual, or treatment as usual with skills training.

Read the detailed description

Suicide is a high priority public health problem and an increasingly prevalent alcohol-related consequence. One-third of people who die by suicide consume alcohol at hazardous rates in the year preceding death. [Most people in an acute suicide crisis who present for treatment are admitted to acute psychiatric hospitalization. Yet, the 30-day period following discharge from hospitalization is by far the riskiest period for another suicide crisis, (post-discharge rates of suicide are 600 times the global rate). Critically, 50% of suicidal inpatients report alcohol misuse, which further heightens post-discharge risk for suicide.

Acute psychiatric hospitalization focuses on rapid crisis resolution before discharging patients back into their environments with a referral for outpatient care. Outpatient-based cognitive-behavioral skills training in emotion regulation successfully treats concurrent alcohol misuse and suicidal behavior by targeting deficits in emotion regulation associated with both behaviors. Yet, fewer than 50% of psychiatric inpatients follow up with outpatient care once discharged, and those who seek care are often unable to receive it for weeks. Persistently low use of outpatient therapies coupled with alarming post-discharge rates of suicide represents an urgent quality gap. Alternative strategies for inpatient care that extend treatment into the critical post-discharge period are clearly needed to prevent suicide in psychiatric inpatients who misuse alcohol.

The specific aim for this project is to evaluate the feasibility and acceptability of an intervention called mHealth-supported Skills Training for Alcohol-Related Suicidality (mSTARS). Inpatients (N = 35) with suicidal thoughts or behaviors who misuse alcohol will be randomized to one of three study conditions: 1) mSTARS (n = 15), 2) treatment as usual (TAU) plus skills training (n = 10), or 3) TAU alone (n = 10). Primary outcomes include feasibility (e.g., recruitment, retention) and acceptability (e.g., patient satisfaction). Secondary outcomes include suicidal thoughts/behaviors, alcohol use, skills utilization, and rehospitalization.

Participants will complete four study visits, including consent and screening, inpatient treatment, post-treatment assessment, and a 3-month follow-up assessment. After the screening visit, participants will be block-randomized to one of three study conditions listed in item 1.a. above. All participants will receive standard inpatient care. Participants randomized to the mSTARS condition will also receive an intervention that combines inpatient skills training and the mHealth telephone app. Inpatient skills training will be completed while participants are receiving inpatient treatment at BHIP. Skills training includes content designed to improve emotional regulation skills, including motivational enhancement, emotional awareness and acceptance, thinking flexibly, changing emotions, countering cravings, and relapse prevention. Upon discharge from Duke BHIP, patients will download the mHealth app on their personal phones to use in the personal environments for 30 days. The app is designed to encourage participants to apply skills acquired in inpatient skills training to real-life situations. Participants assigned to the TAU plus skills training will receive standard inpatient care plus the inpatient skills training described above. Participants assigned to the TAU condition will receive standard inpatient care only. All participants will be seen for a post-treatment assessment at 30-days and 3-months post-discharge.

02

Conditions studied

  • Alcohol Drinking
  • Suicide
03

In context

Alcohol Drinking

703 studies on the registry are indexed under Alcohol Drinking; 132 are open to participants now.

This study's planned enrollment of 35 is below the median of 125 across 609 interventional studies indexed under Alcohol Drinking.

Browse Alcohol Drinking studies →

Lead sponsor

Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.

Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18+
  • hospitalized for suicide crisis at Duke BHIP
  • an AUDIT-C score indicating hazardous past-month drinking (4 for men; 3 for women) + a 90-day calendar timeline follow-back (TLFB) indicating a minimum of 3 heavy drinking days per week on average (per NIAAA standards)
  • owns a smart phone
  • fluent in English.

Exclusion criteria

Exclusion Criteria:

  • current psychotic or mania symptoms indicated by the MINI Neuropsychiatric Interview 6.0.(MINI)
  • receiving ECT at the time of hospitalization, which could inhibit learning
  • engaged in weekly outpatient psychotherapy
  • discharging to another high level of psychiatric care.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    mSTARS

    Participants randomized to the mSTARS condition will receive standard inpatient care while hospitalized at Duke. They will also receive an intervention that combines inpatient skills training and the mHealth telephone app. Inpatient emotional regulation skills training will be completed while participants are receiving inpatient treatment at Duke. Upon discharge from Duke, patients will download the mHealth app on their personal phones to use in their personal environments for 30 days. The app is designed to encourage participants to apply skills acquired in inpatient skills training to real-life situations.

    Behavioral: Standard inpatient psychiatric care · Behavioral: Inpatient Skills Training · Behavioral: mHealth-supported Skills Training for Alcohol-Related Suicidality (mSTARS)

  • Active comparator
    Treatment As Usual

    Participants randomized to the treatment-as-usual condition will receive standard inpatient care provided at Duke.

    Behavioral: Standard inpatient psychiatric care

  • Active comparator
    Treatment As Usual + Skills Training

    Participants randomized to this condition will receive standard inpatient care and inpatient emotional regulation skills training.

    Behavioral: Standard inpatient psychiatric care · Behavioral: Inpatient Skills Training

Interventions

  • BehavioralStandard inpatient psychiatric care

    All participants involved in this study will receive standard of care treatment at Duke University Medical Center's Behavioral Health Inpatient Program.

  • BehavioralInpatient Skills Training

    Inpatient skills training will be completed while participants are receiving inpatient treatment at BHIP. Skills training includes content designed to improve emotional regulation skills.

  • BehavioralmHealth-supported Skills Training for Alcohol-Related Suicidality (mSTARS)

    mSTARS includes inpatient skills training and a mobile health (mHealth) telephone app designed to encourage participants to apply skills acquired in inpatient skills training to real-life situations.

06

What researchers measure

Primary outcomes

  1. Number of participants who are recruited to participate

    This is an indication of feasibility of being able to recruit enough participants in a timely manner into the protocol.

    Time frame: 30 days

  2. Number of participants who complete the post-treatment visit

    Retention will be defined as the number of participants who complete the post-treatment visit that occurs 30 days post-discharge.

    Time frame: 30 days

  3. Number of participants who rate the intervention a 16 or more on the Client Satisfaction Questionnaire.

    Acceptability of treatment will be measured by an 8-item measure designed to evaluate client satisfaction. Scores range from 8 to 32, with higher scores indicating higher satisfaction.

    Time frame: 30 days

  4. Number of participants who score above threshold (34 or more) on the mHealth Satisfaction Questionnaire

    Acceptability of treatment will be measured by a 14-item measure designed to measure usability of mobile health apps. Scores range from 14 to 70. Higher scores indicate higher satisfaction.

    Time frame: 30 days

Secondary outcomes

  1. Average score on the Beck Scale for Suicidal Ideation

    Participants will complete the Beck Scale for Suicidal Ideation, a 19-item scale to assess ideation, plans, and/or intent to suicide. Scores range from 0 to 48, with higher scores indicating higher suicide risk.

    Time frame: 30 days

  2. Average score on the Beck Scale for Suicidal Ideation

    Participants will complete the Beck Scale for Suicidal Ideation, a 19-item scale to assess ideation, plans, and/or intent to suicide. Scores range from 0 to 48, with higher scores indicating higher suicide risk.

    Time frame: 3-month follow-up

  3. Average number of drinking days

    Patients will self-report the number of drinking days in the period between their post-treatment visit and the 3-month follow-up visit.

    Time frame: 30 days

  4. Average number of drinking days

    Patients will self-report the number of drinking days in the period between their post-treatment visit and the 3-month follow-up visit.

    Time frame: 3-month follow-up

  5. Number of participants who report re-hospitalization to an inpatient psychiatry unit.

    Treatment inefficacy will be measured by the number of participants who are re-hospitalized in the 30 day period following their enrollment in the study.

    Time frame: 30 days

  6. Number of participants who report re-hospitalization to an inpatient psychiatry unit.

    Treatment inefficacy will be measured by the number of participants who are re-hospitalized in the 30 day period following their enrollment in the study.

    Time frame: 3-month follow-up

  7. Number of participants who score above 80 on an emotion regulation scale

    Number of participants who score above 80 on an emotion regulation scale

    Time frame: 30 days

  8. Number of participants who score above 80 on an emotion regulation scale

    Number of participants who score above 80 on an emotion regulation scale

    Time frame: 3-month follow-up

  9. Number of participants who score 54 or more on a measure of emotion regulation skills use

    The Emotion Regulation Skills Questionnaire is a 27-item measure of the extent to which an individual was able to successfully use emotion regulation skills typically taught in emotion regulation skills training interventions. Scores range from 0 to 108, and higher scores indicate more successful use of emotional regulation skills.

    Time frame: 30 days

  10. Number of participants who score 54 or more on a measure of emotion regulation skills use

    The Emotion Regulation Skills Questionnaire is a 27-item measure of the extent to which an individual was able to successfully use emotion regulation skills typically taught in emotion regulation skills training interventions. Scores range from 0 to 108, and higher scores indicate more successful use of emotional regulation skills.

    Time frame: 3-month follow-up

  11. Number of participants who score above the clinical range (T score of 70+) on the global severity index of the Symptom Checklist-90

    The Symptom Checklist-90 is A self-report 90-item measure of psychological distress with a T-score range of 30 to 120. Higher scores indicate higher distress.

    Time frame: 30 days

  12. Number of participants who score above the clinical range (T score of 70+) on the global severity index of the Symptom Checklist-90

    The Symptom Checklist-90 is A self-report 90-item measure of psychological distress with a T-score range of 30 to 120. Higher scores indicate higher distress.

    Time frame: 3-month follow-up

  13. Number of participants who score 40 or less on a measure of perceived efficacy to abstain from alcohol

    Participants will complete the 20-item Alcohol Abstinence Self-Efficacy scale indicating how confident they are in ability to abstain from alcohol in certain situations. Scores range from 20 to 100, with higher scores indicating higher confidence to abstain from alcohol use.

    Time frame: 30 days

  14. Number of participants who score 40 or less on a measure of perceived efficacy to abstain from alcohol

    Participants will complete the 20-item Alcohol Abstinence Self-Efficacy scale indicating how confident they are in ability to abstain from alcohol in certain situations. Scores range from 20 to 100, with higher scores indicating higher confidence to abstain from alcohol use.

    Time frame: 3-month follow-up

  15. 18. Number of participants who score 40 or less on a measure of perceived efficacy to abstain from alcohol

    Participants will complete the 20-item Alcohol Abstinence Self-Efficacy scale indicating how confident they are in ability to abstain from alcohol in certain situations. Scores range from 20 to 100, with higher scores indicating higher confidence to abstain from alcohol use

    Time frame: 30 days

  16. 18. Number of participants who score 40 or less on a measure of perceived efficacy to abstain from alcohol

    Participants will complete the 20-item Alcohol Abstinence Self-Efficacy scale indicating how confident they are in ability to abstain from alcohol in certain situations. Scores range from 20 to 100, with higher scores indicating higher confidence to abstain from alcohol use

    Time frame: 3-month follow-up

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Nov 2027, 9 months later.

Of 328 non-industry interventional studies with no phase under Alcohol Drinking, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 9 months is below that.

Counting every sponsor, half of 336 studies reached it within 24 months; a quarter within 11 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Aug 2026 → Feb 2027, primary completion Oct 2027 → Nov 2027 and completion Dec 2027 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2023
First posted
May 6, 2023
StartEst.
Feb 1, 2027was Aug 2026
Primary completionEst.
Nov 30, 2027was Oct 2027
CompletionEst.
Feb 1, 2028was Dec 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2026→Feb 1, 2027
Nov 18, 2026
Primary completion
Oct 30, 2027→Nov 30, 2027
Nov 18, 2026
Study completion
Dec 31, 2027→Feb 1, 2028
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Aug 1, 2026→Feb 1, 2027
    Primary completion Oct 30, 2027→Nov 30, 2027
    Study completion Dec 31, 2027→Feb 1, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05847582
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Feb 1, 2027 (estimated)
Primary completion
Nov 30, 2027 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Jeremy Grove, PhD
Contact
jeremy.grove@duke.edu
919-668-0704
Angela C Kirby, MS
Contact
angela.kirby@duke.edu

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion